Table 1 Demographic and clinical characteristics of all dMMR patients.

From: Stage III deficient mismatch repair colon patients get greater benefit from earlier starting oxaliplatin-based chemotherapy regimen

 

Total (No. %)

Surgery alone group (No. %)

Chemotherapy group (No. %)

p

Sex

0.032

 Male

157 (51.3%)

63 (44.7%)

94 (57.0%)

 Female

149 (48.7%)

78 (55.3%)

71 (43.0%)

Age

0.087

  < 60

120 (39.2%)

48 (34.0%)

72 (43.6%)

  ≥ 60

186 (60.8%)

93 (66.0%)

93 (56.4%)

Depth of tumor invasion (T)

0.393

 T1

12 (3.9%)

8 (5.7%)

4 (2.4%)

 T2

15 (4.9%)

7 (5.0%)

8 (4.8%)

 T3

211 (69.0%)

92 (65.2%)

119 (72.1%)

 T4

68 (22.2%)

34 (24.1%)

34 (20.6%)

Positive lymph nodes (N)

0.867

 0

219 (71.5%)

102 (72.3%)

117 (70.9%)

 1–3

58 (19.0%)

25 (17.7%)

33 (20.0%)

  ≥ 4

29 (9.5%)

14 (9.9%)

15 (9.1%)

TNM

0.601

 1

25 (8.2%)

15 (10.6%)

10 (6.1%)

 2

193 (63.1%)

86 (61.0%)

107 (64.8%)

 3

75 (24.5%)

33 (23.4%)

42 (25.5%)

 4

13 (4.2%)

7 (5.0%)

6 (3.6%)

Histologic grade

0.820

 Low (1/2)

146 (47.7%)

70 (49.6%)

76 (46.1%)

 High (3/4)

110 (35.9%)

49 (34.8%)

61 (37.0%)

 Special type

50 (16.3%)

22 (15.6%)

28 (17.0%)

Location

0.024

 Proximal colon

208 (68.0%)

105 (74.5%)

103 (62.4%)

 Distal colon

99 (32.0%)

36 (25.5%)

63 (37.6%)

Operation

0.432

 Open surgery

219 (71.6%)

104 (73.8%)

115 (69.7%)

 Laparoscopic

87 (28.4%)

37 (26.2%)

50 (30.3%)

Total

306 (100%)

141 (46.1%)

165 (53.9%)